Kornimate/medical-research-clean huggingface dataset:
18f-psma pet/ct for visualization of glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: this is a pilot study to determine uptake of pet tracer 18f-psma-1007 in primary glioblastoma.

glioblastoma multiforme (gbm) is a highly vascularised tumour. previous studies have shown that prostate-specific membrane antigen (psma) is robustly expressed by the tumour vascular endothelium of gbm and thus could be an interesting target for diagnosis and treatment. several groups have focused on the development of 18f-labeled psma ligands for pet imaging. 18f as a radionuclide has several advantages over 68ga. due to the longer half-life compared (110 min for 18f compared to 68 min for 68ga) allows for centralized production and distribution to greater areas. furthermore, multiple doses of 18f can be produced in one synthesis, while each gallium generator provides only one or two elutions per day. moreover, due to the decreased positron energy (0.65 mev for 18f compared to 1.90 mev for 68ga) imaging resolution may be higher. the first generation of 18f-psma ligands, such as 18f-dcfbc, suffered from high background due to slow blood clearance. the second generation 18f-dcfpyl psma ligand has a fast elimination via the urinary route and showed high tumor-to-blood ratios. benesova et al developed the 177lu-dkfz-61, which is suitable for labelling with both diagnostic 68ga as well as therapeutic 177lu (beta-emitting) or 225ac (alpha-emitting), and giesel at al developed 18f-psma-1007, which is structurally related to dkzf-617. since various studies have shown feasibility of psma imaging in brain lesions of patients with recurrent gbm, we want to extend these results in a cohort of patients with a first-diagnosed suspected gbm. we want to use the pet tracer 18f-psma-1007. if this technique can be implemented successfully, the added value of 18f-psma pet/ct for tumour grading and differential diagnosis could be investigated further in larger patient cohorts (especially with recurrent brain lesions). these studies will pave the way for further studies involving 177lu-psma-based therapy, which is currently applied in patients with metastatic prostate cancer.

Eligibility criteria:
inclusion criteria: * suspected gbm on mri scan * scheduled for tumor resection at radboudumc * age ≥18 years exclusion criteria: * age \< 18 years * pregnancy or the wish to become pregnant within 6 months * creatinine clearance below 40ml/min * liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range

Keywords: nuclear imaging prostate specific membrane antigen glioblastoma multiforme positron emission tomography
specific protocoled physiotherapy treatment for subjects surgically treated for femoroacetabular syndrome

Conditions: Hip Injuries

Summary: physiotherapy treatment protocols described in the bibliography after hip surgery are most of them nonspecific. an experimental study is proposed to determine the effectiveness of a protocolized treatment of physiotherapy in the postoperative treatment of femoroacetabular impingement treated by arthroscopy. this study tries to adapt the non-specific post-surgical physiotherapy treatment protocols of the hip to the characteristics of the femoroacetabular impingement and its arthroscopic surgery.


Eligibility criteria:
inclusion criteria: * having suffered hip / groin pain for at least 3 months. * be a patient diagnosed with femoroacetabular syndrome by an orthopedic surgeon based on symptoms, clinical signs and diagnostic imaging. * to have signed the informed consent. * have time available to follow a 14-week physiotherapy treatment program. * be programmed for hip arthroscopy. * be able to speak and understand the spanish language. * be between 18 and 50 years of age. exclusion criteria: * to have received physiotherapy treatment in the last three months. * having previously received hip surgery. * subjects with previous deformities in the femur that severely alter joint mobility such as perthes disease, gliding of the upper femoral epiphysis or avascular necrosis, acetabular fracture, hip dislocation or fracture of the femoral neck. * evidence of preexisting osteoarthritis, defined as tonnis grade\> 2 * subjects with previous deformities in the pelvis that severely alter joint mobility. * any other cardiovascular, psychological and / or cognitive diagnosed pathology that impedes the correct understanding of the study and prevents objective study variables. * subjects that are under the effects of anesthetics or muscle relaxants that mask the sensation of the patient before the techniques of the study. * professional athletes. * subjects in which hip arthroscopy is contraindicated.
a study to evaluate the pain relieving effects, safety, and tolerability of jnj-42160443 for the relief of bladder pain

Conditions: Cystitis, Interstitial; Urologic Diseases; Urinary Bladder Diseases; Cystitis

Summary: the purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of jnj-42160443 compared to placebo in patients with moderate to severe, chronic bladder pain from interstitial cystitis and/or painful bladder syndrome.

this study is a randomized (study drug assigned by chance), double-blind (neither the physician nor the patient knows the name of the assigned drug) study to evaluate the analgesic efficacy, safety, and tolerability of jnj-42160443 compared with placebo in patients with moderate to severe, chronic bladder pain from interstitial cystitis (ic) and/or painful bladder syndrome (pbs). interstitial cystitis (ic) and pbs are urological disorders characterized by symptoms of bladder pain, urinary urgency, urinary frequency, and the need to get up during the night in order to urinate. the study has 3 phases: a screening phase (up to 3 weeks), a double-blind treatment phase (12 weeks), and a post-treatment phase that ends 26 weeks after the last dose of study medication. the study duration will be approximately 36 to 46 weeks. a single dose of jnj-42160443 (9 mg/ml) or matching placebo given as an injection under the skin once every 4 weeks for up to 12 weeks.

Eligibility criteria:
inclusion criteria: * chronic pelvic pain (\>6 months) perceived to be related to the urinary bladder and accompanied by urinary symptoms such as frequent urination during the day and/or night, and/or urgency to void * total score of 8 or greater on the o'leary-sant interstitial cystitis symptom index (icsi) * the mean of the average pain intensity scores at screening phase \>=5 (on a scale of 0 to 10) * medically stable exclusion criteria: * urinary culture is positive for a urinary tract infection; recent invasive therapy to the bladder * history or current conditions indicating that the bladder pain can be caused by diagnoses other than ic/pbs (eg, pain caused by a confirmed or suspected neoplasm) * history of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been successfully treated * women who are pregnant or breast-feeding * a body mass index (bmi) of \>39 kg/m2

Keywords: interstitial cystitis (ic) and/or painful bladder syndrome (pbs)-related pain moderate to severe chronic bladder pain jnj-42160443
comparative investigation of low molecular weight (lmw) heparin/edoxaban tosylate (du176b) versus (lmw) heparin/warfarin in the treatment of symptomatic deep-vein blood clots and/or lung blood clots. (the edoxaban hokusai-vte study).

Conditions: Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis

Summary: evaluation of heparin/edoxaban tosylate (du176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.


Eligibility criteria:
inclusion criteria: * male or female subjects older than the minimum legal adult age (country specific); * acute symptomatic proximal dvt and/or symptomatic pe confirmed at the site by appropriate diagnostic imaging; * able to provide written informed consent exclusion criteria: * thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of dvt and/or pe; * more than 48 hours pre-treatment with anticoagulant therapy prior to randomization; * calculated creatinine clearance (crcl) \< 30 ml/min; * significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or alanine transaminase (alt) \>\\= 2 times the upper limit of normal (uln), or total bilirubin (tbl) x 1.5 times the uln; * patients with active cancer for whom long term treatment with (lmw) heparin is anticipated; * active bleeding or high risk for bleeding contraindicating treatment with (lmw) heparin or warfarin; * chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs (nsaids); * treatment with aspirin in a dosage of more than 100 mg/per day or dual antiplatelet therapy; * concurrent treatment with potent p-gp inhibitors; * subjects with any condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study

Keywords: recurrent thrombosis recurrent pulmonary embolism symptomatic deep vein thrombosis symptomatic pulmonary embolism venous thromboembolism (vte)
prospective evaluation of infectious vulvovaginitis on wound complication rates after vulvar excision for premalignant lesions

Conditions: Vaginitis; Vulvar Diseases

Summary: primary: * to measure the rate of perioperative vulvovaginitis in a population of patients in central va with non-malignant vulvar disease who require surgical excision * to correlate the rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown in patients undergoing spv/wle for vulvar disease we will use a vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (bv), trichomonas, and candida. the swab will be collected preoperatively on day of surgery. the outcome will be evaluated by phone call to patient at 1 week after surgery and physical exam at the postoperative visit between 4-6 weeks.

primary: * to measure the rate of perioperative vulvovaginitis in a population of patients in central va with non-malignant vulvar disease who require surgical excision * to correlate the rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown in patients undergoing spv/wle for vulvar disease we will use a vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (bv), trichomonas, and candida. the swab will be collected preoperatively on day of surgery. the outcome will be evaluated by phone call to patient at 1 week after surgery and physical exam at the postoperative visit between 4-6 weeks.

Eligibility criteria:
inclusion criteria: * must be 18 years of age * has histologically confirmed non-malignant vulvar pathology * is scheduled or planning for wle/spv * signed informed consent obtained prior to any protocol specific procedures exclusion criteria: * unable to give informed consent * women who are pregnant or nursing (lactating) women at time of consent * no prior rt * no recent antibiotic use within the last 3 weeks or 5.5 times the half-life of the antibiotic (whichever is shorter) * no history of prior malignancy within the last 3 years that required systemic chemotherapy or radiation * not immunosuppressed or compromised * no active hiv (must have undetectable viral load) * chronic treatment with corticosteroids or other immunosuppressive agents including topical corticosteroids in the pelvis. inhaled corticosteroids are allowed * no active uncontrolled severe infections (not responding to antibiotics), except acute or chronic pelvic inflammatory disease * uncontrolled diabetes mellitus
rivastigmine patch effect on the post-operative delirium in patients at risk of dementia.

Conditions: Delirium

Summary: delirium is a common and serious condition and is associated with adverse outcome. the elderly who have cognitive dysfunction are expected to show delirium more frequently. it is most likely that delirium represents a response to impaired cholinergic neurotransmission. investigators aimed to establish the preventive effect of the cholinesterase inhibitor, rivastigmine patch, on the post-operative delirium limited to femur neck fracture operation in patients at risk of dementia.

investigators evaluated the delirium prevention effect of rivastigmine patch in patients with femur neck fracture and cognitive impairment. investigators measured the frequency and severity of post-operation delirium in the patch applied and non-applied subjects.

Eligibility criteria:
inclusion criteria: * consecutively enrolled the patients who is going to operation after femur neck fracture. * patients agree to the informed consent. exclusion criteria: * depressive mood and their geriatric depression scale is over 6 / 15. * their korean version mmse(minimental status examination) are over 25, or global dementia scale (gds) are under 3 or over 5. * any delirious state at pre-operation period by dsm iv and cam (confusion assessment method)

Keywords: acetylcholinesterase inhibitors rivastigmine patch post-operational delirium
pseudoexfoliation syndrome, sarcopenia and chronic pain

Conditions: Sarcopenia; Pseudoexfoliation Syndrome

Summary: aim: pseudoexfoliation syndrome (pex) is a systemic disease of connective tissue, it can also contribute to sarcopenia and chronic musculoskeletal pain with common pathways. 1. first aim of this study was to investigate whether the rate of sarcopenia is higher in patients with pex 2. second aim was to investigate the association between pex, sarcopenia parameters and chronic musculoskeletal pain. methods: a total of 96-patients were enrolled in this study and divided into two groups: pex-positive (n=48) and pex-negative (n=48) patients. the variables: the demographic data, sarcopenia parameters (sarc-f-questionnaire, hand-grip strength, chair-rise test, gait speed) and pain parameters (having any chronic musculoskeletal pain, pain regions and visual analogue scale-pain).

sarcopenia is defined as a decreased muscle mass, muscle strength and muscle function, which leads to lower physical performance, disability and quality of life. pseudoexfoliation syndrome (pex) is an age-related, genetic and systemic disease characterized by the accumulation of abnormal extracellular fibrillar material in many ocular and extraocular tissues aim: pseudoexfoliation syndrome (pex) is a systemic disease of connective tissue, it can also contribute to sarcopenia and chronic musculoskeletal pain with common pathways. 1. first aim of this study was to investigate whether the rate of sarcopenia is higher in patients with pex 2. second aim was to investigate the association between pex, sarcopenia parameters and chronic musculoskeletal pain. methods: a total of 96-patients were enrolled in this study and divided into two groups according to having pseudoexfoliation material in ocular tissues: pex-positive (n=48) and pex-negative (n=48) patients. the variables: the demographic data, sarcopenia parameters (sarc-f-questionnaire, hand-grip strength, chair-rise test, gait speed) and pain parameters (having any chronic musculoskeletal pain, pain regions and visual analogue scale-pain).

Eligibility criteria:
inclusion criteria: * being over 60 years * undergoing a detailed complete ophtalmic examination by an experienced physician within 1 month at the department of ophtalmology in the same university hospital. exclusion criteria: * having ophtalmic diseases that cause vision loss and reduce quality of life and mobility smoking, acute/subacute pain, amputation, infection, active arthritis, active cancer, having any protesis or surgery in lower extremities and low back, neurological disorders, malabsorption, weight loss, uncontrolled major systemic diseases, impaired cognitive function and being immobilised.

Keywords: sarcopenia pseudoexfoliation syndrome chronic pain
effect of early implementation of prone positioning

Conditions: Severe Acute Respiratory Syndrome

Summary: background and objective: the ramifications of early lung protective measures and prone positioning on the icu length of stay rates of participants admitted to the icu with acute respiratory distress syndrome amid the covid-19 pandemic constitute a pivotal examination. the study aims to identify the effect of early prone positioning on the length of stay, discharge rate, and number of tracheostomized patients in the icu.

background and objective: the ramifications of early lung protective measures and prone positioning on the icu length of stay rates of participants admitted to the icu with acute respiratory distress syndrome amid the covid-19 pandemic constitute a pivotal examination. the study aims to identify the effect of early prone positioning on the length of stay, discharge rate, and number of tracheostomized patients in the icu. methodology: this retrospective study was conducted on critically ill patients needing mechanical ventilation with lung protective strategy and admitted to the intensive care units of al-azhar university hospitals between march 2020 to april 2022. all patients in the study were interpreted retrospectively by examining the patient's records. group a (n:39) included patients who had been early placed in prone positions within 24 hours of intubation, and group b (n:31) included patients who had not been placed in prone positions. all patients received a lung protective strategy for ards. in both groups, pao2, paco2, ph, spo2, and pao2/fio2 ratio were checked initially and later every 24 hours for 6 days. all patients were evaluated for the total days of both hospital and icu length of stay, number of successful discharges to home from the hospital, and the total number of tracheostomized patients.

Eligibility criteria:
inclusion criteria: * all patients of both sexes. * aged from 18 to 70 years. * body mass index (bmi) from 25 to 35 kg/m2. * critically ill due to ards resulting from covid-19 pneumonia. exclusion criteria: * patients who spent more than 24 hours on mechanical ventilators before enrolment in the study. * patients who died within the first 24 hours of presentation. * patients with advanced cancer. * pregnant patients.

Keywords: prone, lung protective, ards, apachi ii, sofa
determining the effects of sexual health education and counseling given to women in the postpartum period based on the ex-plissit model on sexual life

Conditions: Sexuality; Nurse's Role; Postpartum Disorder

Summary: the aim of this study will be to determine the effect of the sexual health education and counseling program, which is given to women in the postpartum period based on the ex-plissit model, on women's sexual life, including sexual function, sexual distress and sexual life quality.

the study is a multicenter, parallel randomized controlled experimental study with block randomization.for the determination of the working groups, the researcher; will give general information about the research to women who have applied to the family health center and meet the inclusion criteria in the postpartum period of 10 weeks-6 months and agree to participate, and will receive their written and verbal consent for participation.

Eligibility criteria:
inclusion criteria: * being primiparous * having given birth at 38-42 weeks of gestation, * having a single birth, * not experiencing any postpartum complications * the time elapsed from birth is between 10 weeks and 6 months * being sexually active * having a spouse/partner * having a smartphone or computer with a camera * being at least literate exclusion criteria: * a previous sexual function of the woman herself or her husband. * having a chronic disease that she expresses herself (such as cardiovascular disease, hypertension, etc.) * having a health problem that requires the baby to be hospitalized * having received sexual education/counselling * spouse or self-diagnosed mental problem * having a diagnosis that will affect sexual function or body image, such as mastectomy
study of long-term use of forlax® in elderly patients with chronic constipation

Conditions: Constipation

Summary: the main purpose of this study is to evaluate the tolerance of long term repeated doses of forlax® 10g versus lactulose in elderly ambulatory or institutionalized patients, paying special attention to digestive and nutritional status.


Eligibility criteria:
inclusion criteria: * institutionalized patients (in a medical care ward) for at least 3 months, or ambulatory patients * suffering from chronic constipation defined as: * either less than 3 stools per week for at least 3 months and no or partial efficacy of dietary advices, or * patient treated with laxative medication/s for at least 3 months before inclusion, because of chronic constipation corresponding to less than 3 stools per week in case of no laxative treatment * patient has less than 3 stools during 7 consecutive days of the screening wash-out period exclusion criteria: * known organic intestinal disease * having had intestinal surgery * abdominal or pelvic radiation, carcinoma, obstructive disease, malabsorption disease * fecal mass in the rectum which cannot be completely evacuated during the screening wash-out period
speech entrainment for aphasia recovery

Conditions: Aphasia; Aphasia Non Fluent; Stroke

Summary: after a stroke, many people experience a language impairment called aphasia. one of the most debilitating types of aphasia is non-fluent aphasia. non-fluent aphasia is defined by significantly reduced speech production, with the speaker producing only a few words or even less. speech entrainment therapy (set) is a treatment that has been shown to increase fluency in people with non-fluent aphasia. the study looks to define the best dose of set that leads to sustained improvements in spontaneous speech production. participants who are eligible will undergo baseline language testing, an mri, and will be randomized into one of 4 treatment groups: set for 3 weeks, set for 4.5 weeks, set for 6 weeks, and no treatment (control group).


Eligibility criteria:
inclusion criteria * aphasia as a result of a left hemisphere ischemic or hemorrhagic stroke (wab-r aphasia quotient \<93.8). * presence of left hemisphere stroke in clinical imaging (ct/mri) and nihss * participants must have spoken english as their primary language. * 21-81 years old * pre-stroke modified rankin scale (mrs)= 2 or less * post-stroke mrs= 4 or less. * at least 6 months post-stroke. * non-fluent aphasia (wab-r comprehension score \>4 and wab-r fluency score \<6). * technological compatibility (to be determined by clinical judgment of slp) exclusion criteria * history of chronic neurological or psychiatric diseases (excluding migraines, depression, or post-stroke epilepsy). self-reported history of learning disability. * severe dysarthria (determined via slp clinical judgment from spontaneous speech tasks on the asrs 3.0). * global aphasia. * history of right-hemisphere strokes or brain stem/cerebellar strokes with persistent deficits (as evidenced by mri/ct and nihss). * uncorrectable hearing as determined by the slp's clinical judgment. * uncorrectable vision. * contraindications to mri or inability to complete the mri scanning session. * women who are pregnant.

Keywords: aphasia speech language pathology therapy